Contact
Admitted to the Paris Bar in 2024, Mayeul Ottaviani joined August Debouzy the same year.
Specializing primarily in patent law, he provides both advisory and litigation support to French and international clients, defending their interests before national courts and offices and the Unified Patent Court (UPC). He also maintains a strong interest in FRAND matters and broader intellectual property issues.
Mayeul graduated from the University of Montpellier and gained significant experience working with other leading international law firms.
LES France
Master’s degree (Master 2) - Intellectual Property and Digital Law, University of Montpellier
French | English
AD Article
The LD Lisbon Offers Some Limited Insight on Imminent Threat of Infringement
On 8 May 2025, the Lisbon Local Division of the Unified Patent Court (“UPC”) issued an order (Boehringer Ingelheim International GmbH v. Zentiva Portugal LDA, Lisbon LD, 8 May 2025, UPC_CFI_41/2025) denying a preliminary injunction application filed by Boehringer Ingelheim International GmbH (“Boehringer”) against Zentiva Portugal LDA (“Zentiva”).
AD Article
First Unified Patent Court Ruling on Second Medical Use Claims
On 13 May 2025, the Düsseldorf Local Division of the Unified Patent Court issued a landmark decision on the merits relating to a second medical use claim (Sanofi Biotechnology SAS and Regeneron Pharmaceuticals Inc. v. Amgen Inc. et al., 13 May 2025, UPC_CFI_505/2024). The decision follows an infringement action brought by Regeneron and Sanofi, respectively the proprietor and exclusive licensee of European Patent No 3 536 712 ("EP’712"), against various entities of the Amgen group, which subsequently filed a counterclaim for revocation. The claimants argued that the defendants’ product, evolocumab, marketed as Repatha® infringed EP’712.
More
Publications